Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
KYTX
KYTX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
KYTX News
Kyverna Appoints New CFO to Support Product Launch
May 18 2026
seekingalpha
Kyverna Initiates Rolling BLA Process with FDA for miv-cel
May 12 2026
seekingalpha
Kyverna Therapeutics Q1 Earnings Beat Expectations
May 12 2026
seekingalpha
Kyverna Therapeutics Reports Positive Phase 2 Trial Results for Miv-cel in Stiff Person Syndrome
Apr 22 2026
NASDAQ.COM
Kyverna's CAR-T Therapy Shows Significant Mobility Improvements in Clinical Trial
Apr 22 2026
stocktwits
US Stock Futures Edge Up Amid Mixed Market Sentiment
Apr 22 2026
stocktwits
Kyverna's miv-cel Shows Significant Improvement in Stiff Person Syndrome
Apr 21 2026
Newsfilter
Kyverna Therapeutics Shares Surge on Positive Long-Term Trial Data for Miv-Cel
Apr 20 2026
seekingalpha
Kyverna Therapeutics Plans to Raise $300M in Securities Offering
Mar 27 2026
seekingalpha
Kyverna Therapeutics Q4 Earnings Beat Expectations
Mar 26 2026
seekingalpha
Kyverna Presents New Therapies at Neurology Annual Meeting
Mar 05 2026
Newsfilter
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
Dec 31 2025
Benzinga
Biohaven Ltd's Depression Drug Trial Fails to Meet Primary Endpoint, Shares Plunge 14.3%
Dec 26 2025
Benzinga
Weekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO
Dec 20 2025
NASDAQ.COM
Crude Oil Increases by More Than 1%; General Mills Reports Earnings Exceeding Expectations
Dec 17 2025
Benzinga
Kyverna Therapeutics Prices 13.33M Shares at $7.50, Raising Approximately $100M
Dec 17 2025
Newsfilter
Show More News
